Eliaz Therapeutics
company
About
Eliaz Therapeutics is developing a novel treatment using targeted therapeutic apheresis to remove Galetin-3 from the body
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1.70M
- Industries
- Biotechnology,Health Care,Medical Device
- Founded date
- Oct 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
ETI have developed a patented, unique medical device that removes galectin-3 from human blood. The device removes both bound and free galectin-3 from the circulation, offering a new treatment option that is less invasive and has fewer side-effects than other therapies. The single-use apheresis column selectively removes Galectin-3 from the body. It contains a proprietary, highly effective capturing molecule and is built in a format that hospitals already know how to use.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$1.70M
Eliaz Therapeutics has raised a total of
$1.70M
in funding over 2 rounds. Their latest funding was raised on
Jun 23, 2022 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 23, 2022 | Grant | $1.70M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Eliaz Therapeutics is funded by 1 investors.
National Institutes of Health (NIH)
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
